Carbon Nanotube-Based Nanovaccines in Lung Cancer Immunotherapy

Sheikhpour, Mojgan; Sakhi, Hanie

doi:10.52547/vacres.10.2.56

Volume 10, Issue 2 (12-2023) vacres 2023, 10(2): 56-59 | Back to browse issues page

‎ 10.52547/vacres.10.2.56

Mendeley

Zotero

RefWorks

Sheikhpour M, Sakhi H. Carbon Nanotube-Based Nanovaccines in Lung Cancer Immunotherapy. vacres 2023; 10 (2) :56-59
URL: http://vacres.pasteur.ac.ir/article-1-366-en.html

Carbon Nanotube-Based Nanovaccines in Lung Cancer Immunotherapy

Mojgan Sheikhpour ^*

, Hanie Sakhi

Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran. 2Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran

Abstract: (87 Views)

Conventional lung cancer therapies—including surgery, chemotherapy, and radiotherapy—are often limited by insufficient efficacy and significant adverse effects. In response, cancer immunotherapy, particularly vaccine-based approaches, has emerged as a promising strategy to improve outcomes. Carbon nanotubes (CNTs) represent a versatile nanoplatform capable of efficiently delivering antigens, adjuvants, and therapeutic agents, making them attractive candidates for nanovaccine development. This review examines the role of CNT-based nanovaccines in lung cancer immunotherapy, focusing on their mechanisms of action and therapeutic potential. Evidence indicates that CNT nanovaccines enhance antitumor immunity by promoting dendritic cell maturation, stimulating robust humoral and cellular immune responses, and reprogramming the immunosuppressive tumor microenvironment toward an immunopermissive state. Despite these promising preclinical results, clinical translation requires further optimization of CNT design and functionalization, alongside comprehensive in vivo evaluation of immunogenicity, biodistribution, and safety profiles. Overall, CNT-based nanovaccines hold considerable potential to advance lung cancer immunotherapy, though targeted research is needed to bridge the gap between experimental promise and clinical application.

Keywords: Lung cancer, carbon nanotube, nanovaccine, immunotherapy

Full-Text [PDF 473 kb] (34 Downloads)

Type of Study: Review article | Subject: Other
Received: 2026/02/17

Send email to the article author

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.